1. A method for accelerating a plant growth by using a compound represented by formula (1) as an active ingredient for accelerating a plant growth:
wherein R1 and R2 each independently represent a C1-4 alkyl group; Y represents a hydrogen atom, a halogeno group, a C1-4 alkyl group, or a C1-4 haloalkyl group; each R3 independently represents a halogeno group, a cyano group, a nitro group, a C1-4 alkyl group, or a C1-4 haloalkyl group; and n represents the number of R3 and is an integer of 0 to 6.
2. A method for accelerating a plant growth by using 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide as an active ingredient as an active ingredient for accelerating a plant growth.
3. The method for accelerating a plant growth according to claim 1, wherein the method is for seed treatment.
4. A method for growing vigourous seedlings by using a compound represented by formula (1) as an active ingredient for growing vigourous seedlings:
wherein R1 and R2 each independently represent a C1-4 alkyl group; Y represents a hydrogen atom, a halogeno group, a C1-4 alkyl group, or a C1-4 haloalkyl group; each R3 independently represents a halogeno group, a cyano group, a nitro group, a C1-4 alkyl group, or a C1-4 haloalkyl group; and n represents the number of R3 and is an integer of 0 to 6.
5. A method for growing vigourous seedlings by using 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide as an active ingredient as an active ingredient for growing vigourous seedlings.
6. The method for growing vigourous seedlings according to claim 4, wherein the method is for seed treatment.
7. The method for accelerating a plant growth according to claim 2, wherein the method is for seed treatment.
8. The method for growing vigourous seedlings according to claim 5, wherein the method is for seed treatment.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A method of culturing mononuclear cells, comprising:
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells.
2. The method of claim 1, wherein the cells are selected from the group consisting of CD34-, CD14-, CD11-, CD11b-, CD13-, CD64- and CD68-positive cells and endothelial cells.
3. The method of claim 1, wherein the cells are isolated from blood in veins, capillaries, arteries, umbilical cord or placenta, or from bone marrow, spleen, lymph nodes, peritoneal space, pleural space, lymph, veins, arteries, or capillaries, or from connective tissue fluid.
4. The method of claim 1, wherein the culture medium comprises one or more growth factors for endothelial cells.
5. The method of claim 4, wherein the growth factors are selected from the group consisting of growth factors influencing differentiation, survival, migration and vascularization.
6. The method of claim 1, wherein the growth factors are selected from the group consisting of ECGF, FGF, FGF, ECAF, IGF-1; IGF-2; Sl-3; EGF; SCF, TGF, Tie-2-ligands, stromal derived Factor-1, GM-CSF, G-CSF, M-CSF, Sl-4, Sl-1, CSF-1, Sl-8, PDGF, TFN, oncostatin M, BG1, platelet derived endothelial cell growth factor, TNF, angiogenin, pleiotrophin, VEGF, VEGF-B, VEGF-C, VEGF-D, neuropilin, and Flt-3 ligand.
7. A method of making cells capable of expressing a biologically active protein, comprising:
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells;
optionally, before or after culturing the cells, immortalizing the cells; and
transfecting the cells with a nucleic acid construct comprising a gene for the biologically active protein.
8. The method of claim 7, wherein the cells are selected from the group consisting of CD34-, CD14-, CD11-, CD11b-, CD13-, CD64- and CD68-positive cells and endothelial cells.
9. The method of claim 7, wherein the cells are isolated from blood in veins, capillaries, arteries, umbilical cord or placenta, or from bone marrow, spleen, lymph nodes, peritoneal space, pleural space, lymph, veins, arteries, or capillaries, or from connective tissue fluid.
10. The method of claim 7, wherein the culture medium comprises one or more growth factors for endothelial cells
11. The method of claim 10, wherein the growth factors are selected from the group consisting of growth factors influencing differentiation, survival, migration and vascularization.
12. The method of claim 7, wherein the cells are immortalized by a process selected from the group consisting of transforming the cells with an exogenous oncogene; activating an endogenous oncogene; and inactivating an endogenous suppressor gene.
13. The method of claim 12, wherein the exogenous oncogene is linked to an endothelial cell-specific promoter which controls transcription of the oncogene.
14. The method of claim 12, wherein the endogenous suppressor gene is inactivated upon expression of a nucleotide sequence linked to an endothelial cell specific promoter which controls transcription of the nucleotide sequence.
15. The method of claim 7, wherein the biologically active protein is selected from the group consisting of cytokines, chemokines, and growth factors; receptors for cytokines, chemokines and growth factors; proteins having antiproliferative or cytostatic or apoptotic action; antibodies; antibody fragments; angiogenesis inhibitors; peptide hormones; clotting factors; clotting inhibitors; fibrinolytic proteins, peptides or proteins acting on the blood circulation; blood plasma proteins; and antigens of infective agents, cells or tumors, wherein the antigens trigger an immune response.
16. The method of claim 7, wherein the biologically active protein is an enzyme which cleaves a precursor of a drug into a drug.
17. The method of claim 7, wherein the biologically active protein is a ligand-active compound fusion protein or a ligand-enzyme fusion protein, wherein the ligand is selected from the group consisting of cytokines, growth factors, antibodies, antibody fragments, peptide hormones, mediators, cell adhesion proteins and LDL receptor-binding proteins.
18. The method of claim 7, wherein the nucleic acid construct comprises a promoter operably linked to the gene for the biologically active protein.
19. The method of claim 18, wherein the promoter operates cell-specifically, cell cycle specifically, virus specifically, metabolically or by hypoxia.
20. The method of claim 18, wherein the promoter is inducible.
21. The method of claim 7, wherein the nucleic acid construct comprises at least two promoters operably linked to the gene for the biologically active protein, which promoters may be the same or different.
22. A method of effecting gene therapy of a disorder, comprising:
administering to a patient in need thereof a therapeutically effective amount of cells obtained by
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells;
optionally, before or after culturing the cells, immortalizing the cells; and
transfecting the cells with a nucleic acid construct comprising a gene for a biologically active protein useful in the prophylaxis or therapy of the disorder.
23. The method of claim 22, wherein the biologically active protein is selected from the group consisting of cytokines, chemokines, and growth factors; receptors for cytokines, chemokines and growth factors; proteins having antiproliferative or cytostatic or apoptotic action; antibodies; antibody fragments; angiogenesis inhibitors; peptide hormones; clotting factors; clotting inhibitors; fibrinolytic proteins, peptides or proteins acting on the blood circulation; blood plasma proteins; and antigens of infective agents, cells or tumors, wherein the antigens trigger an immune response.
24. The method of claim 22, wherein the biologically active protein is an enzyme which cleaves a precursor of a drug into a drug.
25. The method of claim 22, wherein the biologically active protein is a ligand-active compound fusion protein or a ligand-enzyme fusion protein, wherein the ligand is selected from the group consisting of cytokines, growth factors, antibodies, antibody fragments, peptide hormones, mediators, cell adhesion proteins and LDL receptor-binding proteins.
26. The method of claim 22, wherein the cells are administered externally, orally, intravesically, nasally, intrabronchially, subcutaneously, into the gastrointestinal tract, or are injected into an organ, into a body cavity, into musculature, or into blood circulation.
27. The method of claim 22, wherein the disorder is selected from the group consisting of tumors, leukemias, autoimmune disorders, allergies, arthritides, inflammations, organ rejections, transplant-host reactions, blood clotting disorders, circulation disorders, anemia, infections, hormone disorders and central nervous system (CNS) damage.
28. A method of endothelializing injured vessels, comprising,
administering to a patient in need thereof a therapeutically effective amount of cells obtained by
isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
culturing the cells in a culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells; and
optionally, before or after culturing the cells, immortalizing the cells.
29. A cell obtainable by:
(a) isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal; and
(b) culturing the mononuclear cells in a cell culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells.
30. A pharmaceutical composition comprising the cell of claim 29 and a pharmaceutically acceptable vehicle, carrier, or diluent.
31. A cell for use in gene therapy, obtainable by
(a) isolating mononuclear cells from the blood or cell-containing fluids of the body of a mammal;
(b) culturing the mononuclear cells in a cell culture medium comprising one or more of gangliosides, phospholipids, glycolipids and growth factors for endothelial cells;
(c) optionally, before or after culturing the cells, immortalizing the cells by a process selected from the group consisting of transforming the cells with an exogenous oncogene; activating an endogenous oncogene; and inactivating an endogenous suppressor gene; and
(d) transfecting the cells with a nucleic acid construct comprising a gene coding for a biologically active protein, wherein the nucleic acid construct optionally comprises one or more promoters for expressing the gene for the biologically active protein cell-specifically, cell cycle-specifically, virus-specifically, metabolically or by hypoxia.
32. A pharmaceutical composition comprising the cell of claim 31 and a pharmaceutically acceptable vehicle, carrier, or diluent.